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AbSTRACT
ObJECTIvE To prepare a common Technical 
Document for nitrous oxide (nO) in accordance to European 
guidelines, for submission to the medicine’s Authority to 
obtain a marketing Authorisation (mA) and to carry out a 
project feasibility study.  
mEThOD Directives and guidelines issued by the 
European commission were followed to compile a dossier 
for nO in the common Technical Document (cTD) format, 
in preparation of an abridged application.
kEy fINDINgS The common Technical Document 
gave details on the Administrative Information (module 
1), summaries (module 2), Quality (module 3) and non-
clinical studies (module 4) consisting of a detailed scientific 
bibliography. The active substance manufacturer was 
inspected and accepted as an approved supplier. A feasibility 
study which was conducted proved the project feasible.
CONCLuSION The whole manufacturing process 
of nitrous oxide is well controlled and batches can be 
produced with a constant level of quality. nO has been used 
for 150 years for analgesia and anesthesia and has proven 
safe and effective. Even though its administration is not 
without risks, it currently has a niche role as an inhalational 
analgesic and sedative. 
kEyWORDS nitrous oxide, common Technical 
Document, marketing Authorisation
INTRODuCTION
no medicinal product may be placed on the market in 
malta unless there is with respect to the product a valid 
marketing authorisation (mA) issued by the Licensing 
Authority1	 in	 accordance	with	 EC	Directive	 726/2004.	 The	
key requirement of an application for a mA is the submission 
of a dossier. 
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Figure 1 - common Technical Document format as issued by the Ich
Taken from:
ICH.	M4:	The	Common	Technical	Document	2004	(cited	2014	Feb	19).	Available	from:	www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_
R3_Organisation/M4_R3_organisation.pdf
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The application must be presented in an agreed common 
format known as the common Technical Document 
(cTD), as implemented in July 2003 by the International 
conference on harmonisation (Ich) (figure 1). since nO 
has been widely used in therapeutic practice for several 
decades	 and	 has	 recognised	 efficacy	 and	 an	 acceptable	
level of safety, this medicinal product is defined as having 
a ‘well-established medicinal use’ within Article 10(1)(a)
(ii)	of	Directive	2001/83/EC.2 During initial meetings it was 
established that the company’s intention was to import nO 
in bulk as the active substance. The nO will be stored at the 
company’s premises in cryogenic tanks and will eventually 
be used for filling cylinders.  Batch release of the finished 
products will be carried out by the company’s Qualified 
Person after batch analysis. This project aimed at auditing 
the active ingredient manufacturer and preparing a cTD 
for an application to obtain a marketing authorisation 
through a decentralised procedure. Project feasibility was 
also studied.
mEThOD
The	 official	 audit	 of	 the	 active	 ingredient	 manufacturer	
consisted of sending an Approval of suppliers Questionnaire 
to the potential supplier. The questionnaire was divided into 
six sections including Personnel, Premises and Equipment, 
Documentation,	Quality	Control/Validation,	Batch	Release,	
Production/Operation	 Activities	 and	 Maintenance.	 This	
was followed by a visit to the manufacturer’s premises. An 
official	audit	report	detailing	findings	was	compiled.	
The first undertaking in producing the dossier entailed 
an exhaustive literature review in which an insight was 
gathered on different characteristics of nO. The common 
Technical Document was compiled according to notice 
to	Applicants	Volume	2B	–	Medicinal	Products	 for	human	
use as issued by the European commission in order to 
fulfil the commission’s obligations with respect to article 
6	 of	 Regulation	 (EC)	 No.	 726/20043, and with respect to 
Annex	 I	 of	 Directive	 2001/83/EC.2 module 1 included 
administrative information. Information from the recurrent 
literature review was used to assemble the summary 
of Product characteristics and Labelling and Patient 
Information	Leaflet.	Notice	to	Applicants	–	A	Guideline	on	
summary of Product characteristics issued by the European 
commission4 was used to compile the summary of 
Product characteristics. guidelines issued by the European 
commission - guideline on the readability of the labeling 
of and package leaflet of medicinal products for human 
use, were followed for the compilation of the labeling while 
guidelines issued by the European medicines Agency were 
followed to produce the Patient Information Leaflet.  
In	 accordance	 with	 Articles	 59(3)	 and	 61(1)	 of	 Directive	
2001/83/EC2, a readability study was conducted to ensure 
the safe use of the medicinal gas. A set of 14 multiple 
choice questions were compiled. The Patient Information 
Leaflet and the readability questionnaire were handed to 
ten participants and the collected data was reviewed. After 
satisfactory data was obtained a further ten participants 
were also given the readability questionnaire. forty percent 
of the participants were healthcare professionals, 30% were 
university students and 30% were laypersons. As indicated 
in	 Article	 56a	 of	 Directive	 2001/83/EC2 the name of the 
medicinal product on the packaging was also expressed in 
Braille format. 
The marketing authorisation for nO will be applied for by 
an	abridged	dossier	under	Article	10a	of	Directive	2001/83/
Ec2 relating to the marketing authorisation of medicinal 
products with a well established use. In order to demonstrate 
that nO is a medicinal with a well established use, a 
literature review was undertaken with respect to the first 
uses of nO in sedation and anaesthesia. In accordance with 
Article	8	(ca)	and	(g)	of	Directive	2001/83/EC2 an application 
for marketing authorisation should be accompanied by an 
environmental risk assessment, evaluating any potential 
risks of the medicinal product to the environment. since 
nO is a greenhouse gas with tremendous global warming 
potential, literature sources were evaluated and results 
were drawn up in a report. 
A detailed description of the Pharmacovigilance system 
(DDPs) and an EU Risk management Plan (EU-RmP) were 
compiled	as	outlined	in	Eudralex	Volume	9A.	
Test Specification Analytical Method
Purity ≥	98.0%	V	/	V Infrared
Carbon dioxide ≤	300	ppm	V	/	V gas chromatography
Carbon monoxide ≤	5	ppm	V	/	V gas chromatography
NO + NO2 ≤ 2 ppm chemiluminescence
Water ≤	67	ppm	V	/	V Electrolytic
Table 1 - specifications and Analytical Procedures of nitrous oxide
Taken from:
European	Pharmacopoeia	version	7.3,	Volume	2,	Directorate	of	the	Quality	of	Medicinesof	the	Council	of	Europe,	2012.	Medicines	Conmel	Agency
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Module	3	–	Quality,	detailed	the	quality	of	the	manufacturing	
process for the active substance and the finished product, 
including information about the chemical structure, 
composition, manufacture, quality control, process 
validation and stability, to demonstrate drug manufacture 
control and reproducibility. 
A retrospective validation study of the production process 
was carried out by analysing 20 consecutive batches 
manufactured in 2011. since nitrous oxide has a ‘well-
established medicinal use’, nonclinical studies (module 4) 
consisted of a detailed scientific bibliography giving details 
on pharmacokinetic, pharmacodynamic and toxicological 
studies. no clinical trials were carried out hence there 
was no further information to be presented in module 5. 
module 2 contained summaries and overviews of the 
information presented in detail in the other modules. A 
market analysis was carried out to establish consumption 
figures as part of the project’s feasibility study. costs were 
calculated and the profit and loss schedule was presented. 
By calculating the return on investment after the first 5 years 
one was able to determine the feasibility of this project. 
RESuLTS
The quality system of the Italian manufacturer was deemed 
acceptable and therefore it was accepted as an approved 
supplier. In the patient information leaflet readability 
study, all twelve questions obtained at least sixteen 
correct answers. Eleven participants rated the length as 
adequate, thirteen thought the layout is attractive and 
eighteen considered the letter size acceptable. nine 
participants rated the information conveyed as excellent. 
The well-established use of nO was proven through 
literature. The environmental risk assessment concluded 
that the emission levels for nO are very limited and 
amount to an average of 1.3% of the overall greenhouse 
gas emissions. concerns about the environmental impact 
of the anesthetic use of nO are unfounded as anesthesia 
accounts	 for	 <1%	 of	 total	 NO	 emissions.	 The	 nitrous	
oxide produced meets the specifications required by the 
European Pharmacopoeia (Table 1). 
The manufacturing process of nO is based on the thermal 
decomposition of ammonium nitrate through a pyrolysis 
reaction. The flowchart in figure 2 shows the main stages 
of the process. The analytical methods used are those 
indicated in the European Pharmacopoeia (Table 1). In 
the manufacturing process validation studies, all batches 
conformed to the European Pharmacopoeia specifications 
shown. The minimum and maximum purity results were 
99.7%	and	99.9%	 respectively,	with	 a	median	of	 99.97%.	
The standard deviation values  (Table 2) were very minimal. 
nO is packaged in high pressure cylinders of various 
sizes, contained at a pressure of approximately 60 bar at 
25°c. The different cylinders are identified by their liquid 
volume ranging from 5 liters or less to 50 liters. cylinders 
are made from suitable materials (carbon steel, cr-mo 
steel, stainless steel and aluminum alloys, composite type). 
stamp markings as required by European Directives6 and 
IsO standards are applied on the cylinders’ shoulder. 
Parameter Minimum Maximum Median Std. Dev. RSD
Purity 99.70	% 99.99	% 99.97	% 0.00064 0.00064 %
CO2 3 ppm 6 ppm 4.05 ppm 0.94451 23.32 %
CO 1 ppm 1 ppm 1 ppm 0 0 %
NO + NO2 0.1 ppm 0.2 ppm 0.165 ppm 0.04894 29.66	%
Water 1.1 ppm 3.22 ppm 2.0125 ppm 0.53866 26.77	%
Table 2: manufacturing Process Validation statistical Results
Figure 2: manufacturing Process of nitrous oxide
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The cylinders are fully painted in white with a blue shoulder 
as per standards and are supplied with two main types of 
valves; the pin-index valve or the pressure residual valves. 
The non-clinical studies included the mechanisms of action 
of nitrous oxide both as an anesthetic and an analgesic 
together with its effect on the cardiovascular system, 
respiratory system, central nervous system, muscle, 
kidneys, liver and gastrointestinal tract. The known and 
proposed adverse effects of nO include postoperative 
nausea and vomiting, megaloblastic anaemia, possible 
immunosuppression, myocardial ischaemia, increased 
risk of hypoxia, neural toxicity, possible teratogenicity, 
expansion of air spaces and increased intracranial 
pressure. Attention to occupation exposure limits (OELs) 
is important. facilities to ensure adequate scavenging 
and ventilation are imperative to ensure the occupational 
health of medical staff. Even though, the administration 
of nO is not without risks, it was proven to be safe and 
effective through its use throughout the years.
The five year feasibility study proved the project feasible. 
DISCuSSION
The audit ensured that the product obtained from that 
particular site is up to the required quality standard.  The 
visit to the Italian manufacturer also served for training 
purposes. Training was provided in different aspects of 
production of nO. This visit took place at an early stage 
of this project and served as a good introduction to the 
production process of this medicinal gas. further training 
sessions are planned for other company personnel 
including operators and senior operators. 
The readability study concluded that the Product 
Information presented is legible, clear and easy 
to use. Through ongoing literature searches and 
pharmacovigilance activities, new information available 
will be evaluated and Product Information updated. 
Drug manufacture control and reproducibility are essential 
requirements in module 3 for reviewers of the common 
Technical Document to conclude that the product merits a 
marketing authorisation. By defining the safety parameters 
and the critical control steps of both the manufacturing 
process of the active substance and the manufacturing 
process of the finished product one ensured that the whole 
process is well controlled and that the next batch produced 
is essentially the same as the last batch i.e. batches can be 
produced with a constant level of quality. 
statistical analysis of data recorded confirms that 
the process of production of nO is considered to be 
validated. This feasibility study was conducted by taking 
into consideration the maltese market only, which is 
relatively small and mainly limited to the government 
sector through a tendering process. since the company 
is applying for a decentralised procedure, consumption 
figures will rise considerably if the company manages to 
penetrate foreign markets. This will possibly make the 
project even more feasible. 
CONCLuSION
The whole manufacturing process of nO is well controlled 
and batches can be produced with a constant level of 
quality.
nitrous oxide has been used for 150 years for analgesia and 
anesthesia and has proven safe and effective. Even though 
its administration is not without risks, it currently has a 
niche role as an inhalational analgesic and sedative. 
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